JP2020507626A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507626A5 JP2020507626A5 JP2019564370A JP2019564370A JP2020507626A5 JP 2020507626 A5 JP2020507626 A5 JP 2020507626A5 JP 2019564370 A JP2019564370 A JP 2019564370A JP 2019564370 A JP2019564370 A JP 2019564370A JP 2020507626 A5 JP2020507626 A5 JP 2020507626A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- subject
- composition
- razochido
- nec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 26
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 8
- 206010016654 Fibrosis Diseases 0.000 claims 4
- ORFLZNAGUTZRLQ-ZMBVWFSWSA-N Larazotide Chemical compound NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O ORFLZNAGUTZRLQ-ZMBVWFSWSA-N 0.000 claims 4
- 230000007882 cirrhosis Effects 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 238000013270 controlled release Methods 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 229950000060 larazotide Drugs 0.000 claims 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 4
- 238000013268 sustained release Methods 0.000 claims 4
- 239000012730 sustained-release form Substances 0.000 claims 4
- 206010009895 Colitis ischaemic Diseases 0.000 claims 3
- 201000008222 ischemic colitis Diseases 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010051606 Necrotising colitis Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 208000007944 Nodular Nonsuppurative Panniculitis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010047697 Volvulus Diseases 0.000 claims 1
- 208000026736 Weber-Christian disease Diseases 0.000 claims 1
- 208000026589 Wolman disease Diseases 0.000 claims 1
- 208000004622 abetalipoproteinemia Diseases 0.000 claims 1
- 208000005652 acute fatty liver of pregnancy Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 210000001815 ascending colon Anatomy 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 210000004534 cecum Anatomy 0.000 claims 1
- 210000001731 descending colon Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000001198 duodenum Anatomy 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims 1
- 230000002394 glycogenic effect Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 210000003405 ileum Anatomy 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 201000007647 intestinal volvulus Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 210000001630 jejunum Anatomy 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000001599 sigmoid colon Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000003384 transverse colon Anatomy 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457279P | 2017-02-10 | 2017-02-10 | |
| US62/457,279 | 2017-02-10 | ||
| PCT/US2018/017813 WO2018148655A1 (en) | 2017-02-10 | 2018-02-12 | Compositions and methods for treating disease associated with permeability of intestinal epithelium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020507626A JP2020507626A (ja) | 2020-03-12 |
| JP2020507626A5 true JP2020507626A5 (https=) | 2021-03-25 |
Family
ID=63107916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564370A Pending JP2020507626A (ja) | 2017-02-10 | 2018-02-12 | 腸上皮の透過性と関連する疾患を治療する組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11058902B2 (https=) |
| EP (2) | EP3579862A4 (https=) |
| JP (1) | JP2020507626A (https=) |
| KR (1) | KR20190121785A (https=) |
| CN (1) | CN110891587A (https=) |
| AU (1) | AU2018219367A1 (https=) |
| BR (1) | BR112019016705A2 (https=) |
| CA (1) | CA3052975A1 (https=) |
| MX (1) | MX2019009586A (https=) |
| WO (2) | WO2018148655A1 (https=) |
| ZA (1) | ZA201905439B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11058902B2 (en) * | 2017-02-10 | 2021-07-13 | 9 Meters Biopharma, Inc. | Compositions and methods for treating disease associated with permeability of intestinal epithelium |
| WO2019165346A1 (en) | 2018-02-23 | 2019-08-29 | Innovate Biopharmaceuticals, Inc. | Compounds and methods for treating tight junction permeability |
| US20210100868A1 (en) * | 2018-03-19 | 2021-04-08 | North Carolina State University | Compositions and methods for treating or preventing gastrointestinal damage associated with nsaid therapy |
| WO2019183036A1 (en) | 2018-03-19 | 2019-09-26 | Innovate Biopharmaceuticals, Inc. | Compositions and methods for potentiating immune checkpoint inhibitor therapy |
| WO2021034629A1 (en) * | 2019-08-16 | 2021-02-25 | 9 Meters Biopharma, Inc. | Larazotide formulations |
| AU2021255955A1 (en) * | 2020-04-15 | 2022-11-10 | Interlude Biopharma Co. | Larazotide derivatives comprising d-amino acids |
| WO2023154770A1 (en) * | 2022-02-09 | 2023-08-17 | 9 Meters Biopharma, Inc. | Compositions and methods for inhibiting rho kinase |
| CN114788837B (zh) * | 2022-06-07 | 2023-09-05 | 青岛东海药业有限公司 | 一种组合物及其在制备治疗和/或预防化疗引起的恶心呕吐的药物中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665389A (en) | 1995-05-24 | 1997-09-09 | University Of Maryland At Baltimore | Oral dosage composition for intestinal delivery and method of treating diabetes |
| US5827534A (en) | 1995-05-24 | 1998-10-27 | University Of Maryland At Baltimore | Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery |
| US5945510A (en) | 1997-05-21 | 1999-08-31 | University Of Maryland, Baltimore | Substantially pure zonulin, a physiological modulator of mammalian tight junctions |
| US6458925B1 (en) | 1998-08-03 | 2002-10-01 | University Of Maryland, Baltimore | Peptide antagonists of zonulin and methods for use of the same |
| AU2001249067A1 (en) | 2000-05-19 | 2001-12-03 | University Of Maryland, Baltimore | Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes |
| US20060062758A1 (en) * | 2004-09-21 | 2006-03-23 | Nastech Pharmaceutical Comapny Inc. | Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds |
| US20090176244A1 (en) | 2005-05-13 | 2009-07-09 | Bai Julio | Methods and compositions for the diagnosis of crohn's disease |
| CN101189518A (zh) * | 2005-05-13 | 2008-05-28 | 马里兰巴尔的摩大学 | 评价治疗方案有效性的方法 |
| AR057058A1 (es) * | 2005-06-09 | 2007-11-14 | Alba Therapeutics Corp | Metodo para usar antagonistas de zonulina para prevenir la perdida o para regenerar celulas pancreaticas |
| MX2008010221A (es) * | 2006-02-09 | 2009-03-05 | Alba Therapeutics Corp | Formulaciones para un efector de union ajustada. |
| WO2008043107A2 (en) | 2006-10-06 | 2008-04-10 | Alba Therapeutics Corporation | Use of tight junction antagonists to treat inflammatory bowel disease |
| US8034776B2 (en) | 2006-10-26 | 2011-10-11 | Alba Therapeutics Corporation | Materials and methods for the treatment of celiac disease |
| US20110201543A1 (en) | 2007-06-29 | 2011-08-18 | Blake Paterson | Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress |
| US8198233B2 (en) | 2007-07-26 | 2012-06-12 | Alba Therapeutics Corporation | Synthetic peptides that enhance tight junction permeability |
| WO2009052489A2 (en) | 2007-10-19 | 2009-04-23 | Alba Therapeutics Corporation | Novel inhibitors of mammalian tight junction opening |
| EP2062909A1 (en) * | 2007-11-21 | 2009-05-27 | SOLVAY (Société Anonyme) | Peptide production and purification process |
| US9051349B2 (en) | 2007-11-21 | 2015-06-09 | Alba Therapeutics Corporation | Larazotide acetate compositions |
| CN101440369A (zh) * | 2008-03-26 | 2009-05-27 | 华东师范大学 | 一种缺失的霍乱弧菌封闭带毒素的表达方法及应用 |
| WO2009137572A2 (en) * | 2008-05-06 | 2009-11-12 | Alba Therapeutics Corporation | Inhibition of gliadin peptides |
| WO2010042821A1 (en) * | 2008-10-10 | 2010-04-15 | Nationwide Children's Hospital | Method of treating necrotizing enterocolitis using heparin binding epidermal growth factor |
| EP3125870A4 (en) * | 2014-04-04 | 2017-12-13 | Alba Therapeutics Corporation | Methods of treating celiac disease with larazotide |
| CA2955425A1 (en) * | 2014-07-17 | 2016-01-21 | Jerome Schentag | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
| US11058902B2 (en) * | 2017-02-10 | 2021-07-13 | 9 Meters Biopharma, Inc. | Compositions and methods for treating disease associated with permeability of intestinal epithelium |
-
2018
- 2018-02-12 US US16/484,497 patent/US11058902B2/en active Active
- 2018-02-12 JP JP2019564370A patent/JP2020507626A/ja active Pending
- 2018-02-12 US US16/484,486 patent/US20190358288A1/en not_active Abandoned
- 2018-02-12 BR BR112019016705A patent/BR112019016705A2/pt not_active Application Discontinuation
- 2018-02-12 WO PCT/US2018/017813 patent/WO2018148655A1/en not_active Ceased
- 2018-02-12 KR KR1020197026186A patent/KR20190121785A/ko not_active Ceased
- 2018-02-12 AU AU2018219367A patent/AU2018219367A1/en not_active Abandoned
- 2018-02-12 CN CN201880022687.5A patent/CN110891587A/zh active Pending
- 2018-02-12 MX MX2019009586A patent/MX2019009586A/es unknown
- 2018-02-12 EP EP18750723.1A patent/EP3579862A4/en active Pending
- 2018-02-12 WO PCT/US2018/017811 patent/WO2018148654A1/en not_active Ceased
- 2018-02-12 CA CA3052975A patent/CA3052975A1/en active Pending
- 2018-02-12 EP EP18751409.6A patent/EP3579863A4/en not_active Withdrawn
-
2019
- 2019-08-16 ZA ZA2019/05439A patent/ZA201905439B/en unknown
-
2021
- 2021-06-10 US US17/344,172 patent/US20210299481A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020507626A5 (https=) | ||
| Wang et al. | Gut microbiota in NSAID enteropathy: new insights from inside | |
| Kim et al. | Mind-altering with the gut: Modulation of the gut-brain axis with probiotics | |
| Thompson-Chagoyán et al. | Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response | |
| JP2013525349A5 (https=) | ||
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| JP2021519763A5 (https=) | ||
| JP2016530239A (ja) | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 | |
| Liu et al. | The contribution of the gut-liver axis to the immune signaling pathway of NAFLD | |
| NO20076625L (no) | Derivater av 4- eller 5-aminosalisylsyre | |
| JP2016006125A5 (https=) | ||
| Wang et al. | Gut‑liver axis in liver disease: From basic science to clinical treatment | |
| AU2013255914A1 (en) | A delayed release drug formulation | |
| ZA202002726B (en) | Oral rifamycin sv compositions | |
| JP2012126736A5 (https=) | ||
| EA201100565A1 (ru) | Композиции и способы лечения заболеваний кишечника с использованием гранулированного мезаламина | |
| Yao et al. | The role of small intestinal bacterial overgrowth in obesity and its related diseases | |
| Liu et al. | The farnesoid X receptor agonist tropifexor prevents liver damage in parenteral nutrition‐fed neonatal piglets | |
| JP2021532097A5 (https=) | ||
| Wang et al. | Xylooligosaccharide and Akkermansia muciniphila synergistically ameliorate insulin resistance by reshaping gut microbiota, improving intestinal barrier and regulating NKG2D/NKG2DL signaling in gestational diabetes mellitus mice | |
| JP2015528000A5 (https=) | ||
| EP3890709A1 (en) | Colonic drug delivery formulation | |
| Tursi | Balsalazide plus high-potency probiotic preparation (VSL♯ 3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon | |
| Yue et al. | Role and progression of bile acid metabolism in mediating Th17/Treg homeostasis in inflammatory bowel disease | |
| Saedon et al. | Occult traumatic nasolacrimal duct obstruction causing anophthalmic socket contraction presenting 20 years later: a case report |